14,327 Shares in Exelixis, Inc. $EXEL Acquired by J.M. Arbour LLC

J.M. Arbour LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, HoldingsChannel reports. The fund acquired 14,327 shares of the biotechnology company’s stock, valued at approximately $628,000.

Several other large investors have also recently added to or reduced their stakes in the company. Richardson Financial Services Inc. lifted its holdings in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after buying an additional 292 shares in the last quarter. RHS Financial LLC grew its stake in shares of Exelixis by 2.4% in the fourth quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 293 shares in the last quarter. Cim LLC grew its stake in shares of Exelixis by 0.9% in the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after acquiring an additional 305 shares in the last quarter. Evergreen Capital Management LLC increased its position in Exelixis by 6.4% during the third quarter. Evergreen Capital Management LLC now owns 5,450 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 329 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in Exelixis by 5.1% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,919 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 384 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In related news, SVP Brenda Hefti sold 18,669 shares of Exelixis stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $821,622.69. Following the sale, the senior vice president directly owned 96,512 shares of the company’s stock, valued at approximately $4,247,493.12. The trade was a 16.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Dana Aftab sold 47,918 shares of the stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the completion of the transaction, the executive vice president directly owned 616,106 shares of the company’s stock, valued at approximately $27,416,717. The trade was a 7.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 362,849 shares of company stock worth $15,917,463 in the last quarter. Corporate insiders own 2.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on EXEL shares. Royal Bank Of Canada decreased their target price on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a research note on Monday, January 5th. HC Wainwright increased their price target on Exelixis from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. Finally, Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective for the company. in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Exelixis has a consensus rating of “Hold” and an average target price of $46.94.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $44.38 on Friday. The company’s 50 day simple moving average is $43.03 and its 200 day simple moving average is $42.41. The stock has a market capitalization of $11.53 billion, a price-to-earnings ratio of 16.02, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $49.62.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. During the same period in the prior year, the company earned $0.55 earnings per share. The company’s quarterly revenue was up 5.6% on a year-over-year basis. As a group, analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.